Late Breaking News
ABERDEEN PROVING GROUND, MD - A new study is the first to identify injury rates and identify specific factors increasing injury risk during military police (MP) training in the Army.
RICHMOND, VA - While knee-replacement surgery often is sought so patients can return to a more active lifestyle, patients who undergo the procedure might be at greater risk of gaining weight than those who have not had the surgery.
Chronic infection with hepatitis C virus (HCV) is the most common bloodborne infection in the United States, affecting more than three million Americans. HCV-infected patients are much more likely than the general U.S. population to develop life-threatening complications, such as cirrhosis, end-stage liver disease or hepatocellular carcinoma (HCC). Although antiviral treatment can cure HCV infection, these therapies have historically had low efficacy rates and significant toxicities.
Researchers Trying to Understand Why
DURHAM, NC - Researchers are grappling with the results of a new study that shows an association between increased exercise and reduced risk of prostate cancer in white men but not black men.
Immunization Now Covered for Men Up to Age 27
FALLS CHURCH, VA - In the year since TRICARE added coverage for the human papillomavirus (HPV) vaccine in all males up to age 27, the challenge has been both educating military personnel and their families about the need for the shots and assuring that the recommended three doses are received.
WEST PALM BEACH, FL - How much of a role are clinical pharmacists playing in patient care at VA?
WAYNE, NJ - Tthe U.S. Food and Drug Administration (FDA) has approved Bayer's Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate, according to Bayer HealthCare and Onyx Pharmaceuticals, Inc.
SAN DIEGO - Cadence Pharmaceuticals, Inc. announced that Ofirmev (acetaminophen) injection has been made available on the VA National Formulary (VANF) and must be available for prescription at all VA facilities.
SAN FRANCISCO - The FDA has approved Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy.
TEMPLE, TX - Retired Brig. Gen. James T. Turlington, MD, may no longer be an active duty general officer in the Air Force, but he’s still practicing medicine — and still making a difference.
Most Popular Stories
- Many Healthcare Providers Lose VA Retention Bonuses
- Federal Medicine Organizational Meetings — Tarred with the Same Brush?
- Despite Formulary, High-Cost Diabetes Drug Use Varies Widely Across VA Facilities
- Report Says Administration Faces Hard Choices For Veterans Programs
- Physician Overcomes TBI to Return to Active-Duty Medicine
Join Our E-Mail List